Research progress in targeted therapy for pulmonary squamous cell carcinoma
Pulmonary squamous cell carcinoma is one of the main histological types of lung carcinoma.Unlike pulmonary adenocarcinoma,the benefit from targeted therapy is limited in patients with pulmonary squamous cell carcinoma.Although immunotherapy has significantly improved the prognosis of pulmonary squamous cell carcinoma patients,its relatively low efficacy and associated adverse reactions have restricted its application in pulmonary squamous cell carcinoma patients.There are various mutations in the occurrence and development of pulmonary squamous cell carcinoma.With the further development of molecular biology,epigenetics,and metabolomics,the signaling pathways involved in the pathogenesis of pulmonary squamous cell carcinoma have been continuously studied.Some therapeutic targets have also been studied in clinical practice.Understanding the pathogenesis of pulmonary squamous cell carcinoma and the interrelationship of different signaling pathways is crucial for the development of targeted drugs.Focusing on the epidermal growth factor receptor(EGFR)signaling pathway,vascular endothelial growth factor(VEGF)/vascular endothelial growth factor receptor(VEGFR)signaling pathway,phosphoinositide 3-kinase(PI3K)signaling pathway,cyclin-dependent kinase(CDK)4/6 signaling pathway,etc.,this review aims to provide some insights for targeted treatment of pulmonary squamous cell carcinoma in the future.
NETL
NSTL
万方数据
